CMS Says It Will Spend $3.5 Billion On Leqembi, But This Is Unlikely

Skepticism may be warranted when Medicare says it expects to spend $3.5 billion on the Alzheimer’s disease drug Leqembi.

Related Keywords

United States ,American ,Eli Lilly ,Medpage Todayreports ,Xavier Becerra ,Clinical Trials On Alzheimer Disease Congress ,Medicaid Service Office Of The Actuary ,Department Of Health ,Journal Of The American Medical Association ,Centers For Medicare ,Human Services ,Leqembi May Be ,Medicaid Service Office ,American Medical Association ,Endpoints News ,Human Services Secretary Xavier Becerra ,Clinical Trials ,Disease Congress ,New England Journal ,Kkff ,Medicare ,Leqembi ,Biogen ,Eisai ,Alzheimers Disease ,Aduhelm ,Cms ,Donanemab ,Beta Amyloid Plaque ,